Tobacco smoking is a preventable cause of cardiovascular disease that acts through chronic vascular injury and acute changes in endothelial function, hemostasis, and cardiac workload. It promotes coronary artery disease, stroke, peripheral artery disease, and aneurysmal disease, and may contribute to heart failure and electrical instability. Its effects are not confined to the lungs and do not require cough, dyspnea, or an abnormality on diagnostic testing to be already present.
Exposure may be active or passive, continuous or intermittent, and may involve cigarettes, cigars, pipes, and other combustible products. Nicotine dependence often sustains continued use, whereas a substantial component of cardiovascular toxicity comes from combustion products. Distinguishing these aspects is essential for understanding both the harm and the rationale for nicotine replacement therapy.
No amount of cigarette smoking can be regarded as cardiovascularly safe. The dose–response relationship is particularly steep at low exposure levels: smoking one cigarette a day does not confer merely one-twentieth of the additional risk associated with smoking twenty. Reducing the number smoked may be useful as a step toward abstinence, but it does not provide proportional protection and is not an end goal equivalent to cessation.
Tobacco smoke contains a mixture of particles, gases, and oxidizing substances that reach the respiratory tract and have systemic consequences. Fine particles, reactive aldehydes, and numerous gas-phase compounds can alter cellular signaling, lipoproteins, and endothelial function. Overall toxicity cannot be attributed to a single constituent, nor can clinical safety be inferred from a reduction in just one substance measured in emissions.
Nicotine activates nicotinic receptors in the central nervous system, autonomic ganglia, and adrenal medulla. Increased sympathetic activity and catecholamine release can accelerate heart rate, increase blood pressure and contractility, and alter vascular tone. In a heart with limited coronary reserve, increased oxygen demand may aggravate a mismatch between supply and demand. Route of administration and the rapidity of concentration peaks influence both hemodynamic effects and dependence potential.
Carbon monoxide binds to hemoglobin and reduces effective oxygen transport, also altering oxygen release to tissues. Exposure to combustion thus adds reduced oxygen availability to increased cardiac workload. Carboxyhemoglobin may be elevated without conventional pulse oximetry accurately reflecting the phenomenon; it is measured when the clinical question warrants it, particularly when poisoning is suspected.
Endothelial dysfunction includes reduced nitric oxide bioavailability, impaired vasodilation, and increased expression of signals promoting leukocyte adhesion and inflammation. These changes may arise before detectable stenoses develop. Lipoprotein oxidation and retention are part of an atherogenic process already driven by exposure to apoB-containing particles; smoking accelerates this process without replacing the causal role of lipoproteins.
Conditions favoring thrombosis increase in blood and within the vascular wall. Platelet activation, changes in fibrinogen, and reduced fibrinolytic efficiency may facilitate thrombus formation and persistence when a plaque becomes complicated. This component helps explain why some of the benefits of cessation begin before the atherosclerotic burden can change substantially.
Vasospasm and altered vasomotor function can contribute to ischemia, even when stenoses do not fully explain the symptoms. Coronary angiography showing no major obstructions therefore does not exclude every possible ischemic mechanism. A history of smoking informs the assessment, but does not by itself prove that an episode of pain is caused by spasm and does not replace appropriate investigations.
Autonomic instability, ischemia, and effects on myocardial electrical properties may favor arrhythmias. Risk also depends on the structural substrate, electrolytes, and medications; palpitations are not a reliable measure of toxicity, and their absence does not make exposure harmless. In patients with a previous myocardial infarction or heart failure, cessation complements treatment of the heart disease and specific measures to prevent sudden cardiac death.
In the aorta, smoking is strongly associated with the development and progression of abdominal aortic aneurysms. Inflammation and matrix remodeling contribute to disease of the arterial wall that is not simply atherosclerotic stenosis. In limb artery disease, continued smoking worsens the course and may compromise the durability of revascularization benefits. Thromboangiitis obliterans is also a distinct vascular disease strongly linked to tobacco and should be recognized in appropriate clinical phenotypes.
Secondhand smoke exposes nonsmokers to substances capable of altering endothelial and platelet function. The sensitivity of cardiovascular pathways to low doses helps explain why environmental exposure cannot be regarded as a negligible fraction of active smoking. Protecting home and workplace environments and supporting household members in quitting complement individual prevention.
Injury may remain clinically silent until an event occurs. Angina, reduced exercise tolerance, claudication, transient neurological deficits, or heart failure may be the first recognized manifestation. Cough and dyspnea also suggest respiratory disease, but should not prevent consideration of a concomitant cardiac cause. In smokers with dyspnea, several mechanisms often coexist and must be distinguished so that they can be treated.
Smoking history includes age at initiation, duration, and consumption, periods of abstinence, any resumption, and products used. Pack-years are calculated by multiplying the number of packs smoked per day, conventionally containing twenty cigarettes, by years of smoking. They summarize exposure but are not a biological dosimeter: inhalation depth, changes over time, and different products may make a single figure unrepresentative.
For nonconventional products, record the product type and pattern of use, frequency, nicotine content if any, and concurrent cigarette smoking. Cigar, pipe, or waterpipe use should not be arbitrarily converted into cigarette equivalents. A patient's report of not inhaling deeply does not exclude nicotine absorption or exposure to toxic substances. It is also useful to ask explicitly about occasional use, which is often not perceived as “being a smoker.”
Assessment of dependence considers urgency to smoke upon waking, difficulty refraining, withdrawal symptoms, and previous attempts to quit. Time to first cigarette and instruments such as the Fagerström test can help determine the intensity of support required. Motivation to change is important but is not synonymous with dependence: a highly motivated person may still need pharmacotherapy and frequent follow-up contacts.
Previous attempts help identify reasons for relapse, medications already tried, adverse effects, increased appetite, stress, and social settings. Mood disorders, problematic alcohol or other substance use, and conditions influencing treatment choice should be assessed. The interview should avoid judgment: shame and fear of being reprimanded may encourage omissions, particularly among patients with heart disease who need more intensive help.
Physical examination includes blood pressure, cardiac rhythm, and pulses, signs of congestion, and respiratory assessment. Ischemic limb lesions or diminished pulses warrant vascular evaluation; a bruit or an abdominal finding may prompt targeted investigations. However, there is no sufficiently accurate “smoker's appearance” for quantifying exposure or harm, and skin or dental findings do not replace the medical history.
Exposure is diagnosed primarily from the history. Exhaled carbon monoxide can support monitoring of smoking cessation, but mainly reflects a recent interval and is affected by other sources of combustion. A low result does not rule out intermittent smoking or products that do not produce CO; nor does it certify the absence of previous cardiovascular risk.
Cotinine, a nicotine metabolite, documents nicotine absorption in different biological specimens. On its own, it cannot distinguish cigarettes, therapeutic substitutes, and other nicotine products. Biomarker selection therefore depends on the question: confirming nicotine exposure differs from verifying abstinence from combustion. Results should be used to improve care, not as a punitive tool.
The risk profile includes lipids, blood pressure, glucose, and kidney function as appropriate to the context. Smoking can markedly increase risk even when these parameters are favorable. Models treating smoking as a binary variable do not always adequately capture intensity, duration, and time since cessation; the number generated by an algorithm must be interpreted alongside the clinical history.
Suspicious chest pain or acute dyspnea requires assessment for acute coronary syndrome, including ECG and troponin testing according to timing and clinical presentation. Tobacco use is a factor affecting probability, not a sufficient diagnostic criterion. Events can occur even in young people; conversely, attributing all pain to the heart solely because of smoking may lead to inappropriate assessments.
For stable symptoms, investigation of coronary or peripheral artery disease follows anatomical and functional indications. The ankle–brachial index and duplex Doppler ultrasound may be useful for limb symptoms; coronary imaging is selected according to probability and the clinical question. An asymptomatic smoker does not automatically need coronary angiography or repeated routine ischemia tests. Cessation remains indicated even without instrumental evidence of atherosclerosis.
After a cardiovascular diagnosis, the vascular territories involved and disease severity, ventricular function, exercise limitations, and need for rehabilitation are established. These factors guide treatment of heart disease and the circumstances of cessation. Hospitalization for myocardial infarction may provide a favorable opportunity, but enforced abstinence during the stay does not establish that dependence has resolved and must be followed by a discharge plan.
Medication selection requires a targeted clinical review of kidney function, blood pressure, seizure history, eating disorders, psychiatric status, pregnancy, and concomitant drugs. Extensive testing is not needed before offering every patient help, but conditions that alter safety and dosing must be identified. Stable heart disease and acute instability should not be treated as equivalent situations.
Smoking cessation can change drug metabolism. Some combustion products induce enzymes, particularly CYP1A2; cessation may increase exposure to drugs metabolized through this pathway, such as clozapine or theophylline. The effect depends on smoking, not simply on nicotine exposure, and may occur even while nicotine replacement is being used. Medication reconciliation makes it possible to plan appropriate monitoring and adjustments.
The plan establishes a quit date, support, and follow-up visits, identifies high-risk situations for relapse, and sets out how to manage cravings. Expected benefits and possible temporary withdrawal symptoms are explained. Involving household members, access to a smoking cessation service, and integration with rehabilitation improve continuity, especially when the patient must also manage many new cardiovascular prescriptions.
WHO guidelines recommend behavioral support and pharmacotherapy as complementary components of tobacco cessation in adults. Brief, clear advice is useful, but persistent dependence warrants a proportionate intervention: individual or group counseling, telephone contacts, and digital tools can support the program. Choice takes account of preferences, accessibility, and previous experiences, without reducing the process to issuing a prescription.
Nicotine replacement therapy alleviates withdrawal symptoms by providing nicotine without combustion products. A patch provides relatively steady delivery; gum, lozenges, and other short-acting formulations help manage episodic cravings. Combining a longer-acting with a faster-acting formulation may be more effective than using one alone. Dose and use should be sufficient to control symptoms, avoiding undertreatment that encourages early resumption of smoking.
Therapeutic nicotine is not devoid of hemodynamic effects, but its risk profile differs from that of cigarettes. In stable cardiovascular disease, replacement is generally a feasible option, and fear of nicotine should not leave patients exposed to combustion. After a recent acute coronary syndrome, with significant arrhythmias, or with hemodynamic instability, treatment choice and monitoring are agreed with the treating team. Palpitations, nausea, and signs of excessive exposure require reassessment of the dose and concurrent tobacco use.
Varenicline is a partial nicotinic receptor agonist that alleviates withdrawal and reduces the reward from smoking. It is introduced by dose titration and incorporated into a program lasting several weeks, which may be extended according to response. Nausea and sleep disturbances are common adverse effects; renal elimination calls for attention when kidney function is impaired. Proper use requires explaining its onset of action and managing adverse effects rather than stopping it at the first discomfort without considering alternatives.
Bupropion acts on noradrenergic and dopaminergic systems and is another cessation option. Insomnia, dry mouth, and increased blood pressure may affect its use. A history of seizures, certain eating disorders, abrupt withdrawal of substances affecting the seizure threshold, and drug interactions call for particular caution or constitute contraindications according to the product information. Mood assessment and review of psychiatric treatments should precede any automatic choice.
Cytisine, also a partial nicotinic agonist, is among the effective options considered by WHO. Availability, formulations, and authorized regimens vary by setting; it is inappropriate to transfer the dosing schedule of one preparation to another. For all medicines, pregnancy, breastfeeding, comorbidities, and combinations require specific assessment. Evidence in the general adult population does not automatically amount to a recommendation for every population.
The EAGLES trial compared varenicline, bupropion, nicotine patches, and placebo in smokers with and without psychiatric disorders, providing evidence on efficacy and neuropsychiatric safety. The subsequent cardiovascular assessment found no significant differences in major events between treatments in the population studied. These findings support offering effective therapies but do not remove the need for clinical selection or constitute unlimited evidence for all acute or unstable cardiovascular conditions.
Withdrawal symptoms may include irritability, restlessness, impaired concentration, increased appetite, and sleep disturbances. Cravings tend to recur in situations associated with smoking even after the initial symptoms improve. Preparing practical responses, adjusting medication, and maintaining follow-up contact help distinguish a predictable phase from failure of the program. Significant depressive symptoms or other clinical changes nevertheless require assessment in their own right.
Possible weight gain after cessation warrants prevention and monitoring, especially in diabetes or obesity, but does not negate the benefits of quitting. Nutrition, physical activity, and appetite management should be incorporated without setting unrealistic simultaneous goals. Continuing tobacco use as a weight-control strategy is inappropriate; treatment of metabolic conditions offers safer approaches consistent with prevention.
In the Cochrane review updated in 2026, nicotine-containing electronic cigarettes showed a higher probability of smoking cessation than nicotine replacement therapy in the available comparisons. This outcome concerns quitting combustible cigarettes and must be distinguished from long-term cardiovascular safety: study durations, device heterogeneity, and the rarity of events do not allow prolonged exposure to be declared harmless. The aerosol is not simply water vapor, and dependence may persist.
Dual use of cigarettes and electronic products is not equivalent to completely replacing combustion. Continuing to smoke even a few cigarettes preserves a substantial component of vascular risk, so a lower number smoked is insufficient to demonstrate a clinically equivalent risk reduction to cessation. The clinical discussion establishes what the person actually uses and keeps the goal of treatment explicit, without equating all products or assigning universal percentages of harm reduction.
Heated tobacco differs from electronic cigarettes and cessation medications. Reductions in some toxic substances in emissions do not in themselves demonstrate proportional reductions in myocardial infarction or mortality; evidence for one product cannot be transferred to another. Introducing nicotine products to nonsmokers is not cardiovascular prevention. Clinical communication should clarify which outcomes have been measured and which remain uncertain.
Relapse is common in dependence and calls for reassessment of circumstances, not withdrawal of care. An isolated lapse can be addressed early before it becomes a sustained return to smoking. Dose, duration, support, social contexts, and comorbidities are reassessed; a previous partial response does not rule out benefit from repeating or modifying treatment. In people with heart disease, coordination among smoking cessation services, the primary care physician, and rehabilitation facilitates this transition.
Concomitant cardiovascular prevention retains its indications. Statins, antihypertensives, and antithrombotic therapies are selected according to risk and disease, not used to offset continued smoking. After revascularization, quitting tobacco protects a vascular system that remains exposed even outside the treated segment. Regular review covers tobacco use, symptoms, medication tolerability, and cardiovascular goals.
After cessation, certain hemodynamic and thrombotic components improve rapidly, whereas the risk associated with already established structural disease takes longer to decline. In the cohort analyzed by Duncan and colleagues, heavy smokers who quit showed a reduction in cardiovascular risk within five years compared with those who continued; approaching the risk of never-smokers required a longer time horizon. Thus, there is no individual deadline after which every component of risk automatically returns to normal.
In established coronary artery disease, cessation is associated with lower mortality and a more favorable course. The review by Critchley and Capewell documented a substantial risk reduction in people who stopped smoking, based on prospective cohorts. Observational evidence requires attention to confounding, but is consistent with biological mechanisms and the overall body of evidence making cessation a priority in secondary prevention.
Continued smoking may promote recurrent ischemic events, progression of peripheral artery disease, loss of benefit after procedures, and aneurysmal complications. Respiratory disease and cancer add morbidity, limit exercise capacity, and may complicate cardiac treatment. Prognostic assessment must encompass these outcomes rather than being confined to the probability of a single myocardial infarction.
Cessation remains beneficial even at an advanced age and after many years of exposure. The magnitude of benefit depends on the starting situation, but accumulated damage does not make preventing further damage pointless. Follow-up supports abstinence and continued surveillance of documented diseases: quitting changes the course without eliminating the need to treat already established heart disease.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.